Identification of serum prognostic biomarkers of severe COVID-19 using a quantitative proteomic approach.
Biomarkers
/ blood
COVID-19
/ blood
COVID-19 Serological Testing
/ methods
Chitinase-3-Like Protein 1
/ metabolism
Enzyme-Linked Immunosorbent Assay
Gas Chromatography-Mass Spectrometry
Gene Expression Profiling
Gene Expression Regulation
Humans
Inflammation
Interleukin-1beta
/ biosynthesis
Interleukin-6
/ biosynthesis
Prognosis
Proteomics
/ methods
SARS-CoV-2
Tumor Necrosis Factor-alpha
/ biosynthesis
Virus Diseases
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
19 10 2021
19 10 2021
Historique:
received:
27
01
2021
accepted:
06
09
2021
entrez:
20
10
2021
pubmed:
21
10
2021
medline:
16
11
2021
Statut:
epublish
Résumé
The COVID-19 pandemic is an unprecedented threat to humanity that has provoked global health concerns. Since the etiopathogenesis of this illness is not fully characterized, the prognostic factors enabling treatment decisions have not been well documented. Accurately predicting the progression of the disease would aid in appropriate patient categorization and thus help determine the best treatment option. Here, we have introduced a proteomic approach utilizing data-independent acquisition mass spectrometry (DIA-MS) to identify the serum proteins that are closely associated with COVID-19 prognosis. Twenty-seven proteins were differentially expressed between severely ill COVID-19 patients with an adverse or favorable prognosis. Ingenuity Pathway Analysis revealed that 15 of the 27 proteins might be regulated by cytokine signaling relevant to interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF), and their differential expression was implicated in the systemic inflammatory response and in cardiovascular disorders. We further evaluated practical predictors of the clinical prognosis of severe COVID-19 patients. Subsequent ELISA assays revealed that CHI3L1 and IGFALS may serve as highly sensitive prognostic markers. Our findings can help formulate a diagnostic approach for accurately identifying COVID-19 patients with severe disease and for providing appropriate treatment based on their predicted prognosis.
Identifiants
pubmed: 34667241
doi: 10.1038/s41598-021-98253-9
pii: 10.1038/s41598-021-98253-9
pmc: PMC8526747
doi:
Substances chimiques
Biomarkers
0
CHI3L1 protein, human
0
Chitinase-3-Like Protein 1
0
IL1B protein, human
0
IL6 protein, human
0
Interleukin-1beta
0
Interleukin-6
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
20638Subventions
Organisme : the Japan Agency for Medical Research and Development
ID : JP19fk0108169
Organisme : the Japan Agency for Medical Research and Development
ID : JP19fk0108110
Informations de copyright
© 2021. The Author(s).
Références
JAMA. 2020 Sep 3;:
pubmed: 32880615
Inflamm Res. 2020 Sep;69(9):825-839
pubmed: 32529477
JAMA Intern Med. 2020 Aug 1;180(8):1081-1089
pubmed: 32396163
Sci Rep. 2017 Mar 06;7:43732
pubmed: 28262744
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D433-7
pubmed: 15608232
Biomed Res Int. 2018 Jun 19;2018:6057589
pubmed: 30018981
Innovation (N Y). 2020 May 21;1(1):100007
pubmed: 33554186
Life Sci. 2020 Aug 1;254:117788
pubmed: 32475810
Int J Cardiol. 2010 Aug 6;143(1):35-42
pubmed: 19223085
Cell Syst. 2020 Jul 22;11(1):11-24.e4
pubmed: 32619549
Endocrinology. 2001 Oct;142(10):4305-13
pubmed: 11564688
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6868-73
pubmed: 10823924
Int J Surg. 2020 May;77:217
pubmed: 32305321
Endocr Rev. 1997 Dec;18(6):801-31
pubmed: 9408744
Respir Med. 2010 Aug;104(8):1204-10
pubmed: 20347285
JAMA Intern Med. 2020 Sep 1;180(9):1152-1154
pubmed: 32602883
Eur J Epidemiol. 2021 Mar;36(3):311-318
pubmed: 33420872
Crit Care Med. 2015 Dec;43(12):2651-9
pubmed: 26427594
Signal Transduct Target Ther. 2020 Oct 3;5(1):217
pubmed: 33011738
Nat Rev Immunol. 2020 May;20(5):271-272
pubmed: 32296135
Clin Exp Immunol. 2008 Feb;151(2):260-6
pubmed: 18070151
Nat Protoc. 2007;2(8):1896-906
pubmed: 17703201
J Proteome Res. 2020 Nov 6;19(11):4219-4232
pubmed: 32657586
Eur J Endocrinol. 2012 Jan;166(1):121-9
pubmed: 22004906
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Proteome Sci. 2008 Feb 26;6:9
pubmed: 18302743
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
Sci Rep. 2020 Dec 29;10(1):22418
pubmed: 33376242
Int J Chron Obstruct Pulmon Dis. 2020 Apr 23;15:885-899
pubmed: 32368034
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Eur J Immunol. 2020 Jul;50(7):932-938
pubmed: 32438473
Cell. 2020 Jul 9;182(1):59-72.e15
pubmed: 32492406
Respir Res. 2016 Mar 24;17:31
pubmed: 27013031
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
PLoS One. 2011;6(8):e23385
pubmed: 21858095
Nat Rev Cardiol. 2020 Sep;17(9):543-558
pubmed: 32690910